Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Brinter

Brinter develops 3D bioprinted implants to replace conventional implants and restore damaged body parts
2020
02-Oct
02-10
North Carolina, United States
  • Drug Delivery and Devices
  • Personalized Medicine Technologies

Innovation

Industry Problem

Tissue engineering requires flexible bioprinters that can handle multiple biomaterials and move from research toward clinical manufacturing.

R&D Focus

Modular 3D bioprinting, biofabrication automation and bioabsorbable implants.

Innovative Solution

A modular multi-material printing platform allows laboratories to combine different printheads, biomaterials and automation workflows.

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

$4.52M

Last Funding Amount

$1.31 M

Last Funding Date

6/21/2025

Startup Stage

Early Stage

Lead Investors

Techstars, ProHealth Growth, Winston Starts, Athensmed, Innovestor

People

Founders

CEO

About

Brinter develops 3D bioprinted implants to replace conventional implants and restore damaged body parts

Products

Product

Brinter ONE modular 3D bioprinter and automated biofabrication systems.

Star Product

Brinter ONE, because it is the company’s core commercial platform and supports multiple printing modalities.

Demo Product or Complete Product?

Brinter ONE is a commercial research-use printer; implant programs remain investigational and are not approved medical products.

Future Plan

Market Expansion

The company has stated that it is preparing for broader US commercialization and clinical-development partnerships.

Investment Funding

Raised €1.2 million in seed funding in 2021 to accelerate bioprinter development and market growth.

Something missing or incorrect on this page? Help us enrich this information